Aegis Therapeutics has announced that it received its first Russian patent (No. 2554814), titled, “Compositions for drug administration.” The patent covers formulations of triptans for the treatment of migraine that use Aegis’ Intravail transmucosal absorption enhancers. According to the company, the Intravail formulation results in the achievment of clinically effective levels of the drug approximately 20 times faster than a currently marketed intranasal triptan.
The company also recently announced that it had received Chinese and Japanese patents for delivery of triptans. Aegis said that it now has 25 patents issued and 50 pending applications worldwide.
Read the Aegis press release on the Russian patent.
Read the Aegis press release on the Chinese and Japanese patents.
